eRapport

ACRedIT: Advanced ColoRectal Cancer – Individualization of Therapies

Prosjekt
Prosjektnummer
2014012
Ansvarlig person
Anne Hansen Ree
Institusjon
Akershus universitetssykehus HF
Prosjektkategori
Regionalt forskningsnettverk
Helsekategori
Forskningsaktivitet
Rapporter
2016 - sluttrapport
Som bakgrunn vises til de faglige rapportene for 2014 og 2015, samt informasjon på nettverkets nettside www.acredit.no. Gjennom 2016 har nettverket utviklet et nytt satsingsområde innen immunterapi for avansert colorectal cancer, hvor vi i løpet av 2017 skal starte en skandinavisk, multisenter, randomisert fase 2-studie. Per januar 2017 har ni norske sentra og ett dansk senter tilsagt deltagelse i studien, som videre skal presenteres for ytterligere to danske og tre svenske sentra i løpet av april 2017 med forventning om at disse også vil ønske å delta. For å finansiere denne bredt anlagt klinisk-translasjonelle behandlingsstudien, mottok nettverksdirektøren (prosjektleder) i 2016 på vegne av nettverket NOK 8M fra Kreftforeningen (Grant 182496), NOK 800K som gaveforsterkingsmidler via Universitetet i Oslo og senest NOK 6M fra Helse Sør-Øst for å kontinuere nettverket i ytterligere tre år (Grant 2017109). Prosjektleder planlegger også søknad til KLINBEFORSK-programmet i april 2017 for finansiering og gjennomføring av studien. Vår andre store satsning innen nye behandlinger er det internasjonale Cure4PMP-konsortiet for pseudomyxoma peritonei, hvor planen er å søke midler innen Horizon 2020-programmet når det kommer en utlysning innen sjeldne sykdommer. Dette initiativet arbeides det med kontinuerlig mellom partnerne i Norge, England, Frankrike og Belgia, hvor ACREDIT-nettverket er det koordinerende senteret. Vår tredje store satsning er å videreutvikle de nye funksjonelle MR-teknikkene som er utviklet innen en av nettverkets pågående rectumcancerstudier. Den teknikken vi har ansett som mest lovende har vi i samarbeid med Inven2 lagt inn søknad om patentering av (Dehns Patent and Trade Mark Attorneys, Patent 12.128509). Vi har fortsatt arbeidet med kompetanseheving og styrking av forskningsgruppenes felles satsningsområder gjennom seminarer og workshops for alle nettverket deltagere og spesielt med henblikk på de yngre prosjektdeltagerne (doktorgradsstudenter, postdoktorer og teknisk personale). For tiden har nettverket så mange som 10 felles, pågående doktorgradsstudenter. I de neste tre årene vil nettverket også ha deltagere fra et ikke-universitetssykehus (Vestre Viken – Drammen). I september 2016 gjennomførte vi et vellykket møte med vårt internasjonale Scientific Advisory Board. Videre har vi fått på plass formelt samarbeid med NORILCO (Norsk forening for stomi, reservoar og mage- og tarmkreft) som brukerorganisasjon. Nettverksdeltagere har vært synlig i media. For tiden har nettverket ni pågående klinisk-translasjonelle studier i sin portefølje. Som nevnt over har nettverkets pågående aktivitet potensiale til å utvikle to nye behandlingsmetoder og én ny diagnostisk metode. Den første gjelder immunterapi som førstevalg innen avansert colorectal cancer og vil således omfatte en betydelig pasientgruppe. Den andre gjelder nye kirurgiske og onkologiske teknikker innen pseudomyxoma peritonei og vil således omfatte en liten pasientgruppe som i dag har svært begrensede behandlingsmuligheter. Den tredje gjelder funksjonell MR-diagnostikk innen rectumcancer med hensyn på mer presise behandlingsvalg og vil således omfatte en betydelig pasientgruppe.
2015
Som bakgrunn for den faglige rapporten for 2015 for ACREDIT-nettverket vises til rapporten for 2014. I det andre prosjektåret har nettverket fokusert på blant annet kompetanseheving og videre oppbygging av internasjonale relasjoner, samt styrking av forskningsgruppenes felles satsningsområder, for eksempel innen immunterapi, gjennom seminarer og symposier. • Nettverkets forskningskoordinator har deltatt på forskjellige kurs om forskningsadministrasjon i Europa, samt kurs om Horizon 2020-programmet: o NARMA (norsk nettverk for forskningsadministrasjon) sin vårkonferanse, 13.-14. april 2015 i Oslo. o Europa Media Training Course, EU Research and Innovation Proposal Development, 16.-17. april 2015 Brüssel. o Informasjonsmøte om MSCA Individual Fellowships, Norges Forskningsråd, 6. mai 2015 i Oslo. • Strategier rundt Horizon 2020-programmet: o Horizon 2020 Health Partnering Day 2015, 17. september 2015 i Brussel: Presentasjon av ACREDIT-nettverket og Cure4PMP-konsortiet. o Open Info Day Horizon 2020, 18. september 2015 i Brussel, hvor den europeiske kommisjonen presenterte det nye arbeidsprogrammet i “Health, Demographic Change and Well-being”, hvor vi fikk gjennomgått og stilt spørsmål om utlysningen ”SC1-PM-03–2017: Diagnostic Characterisation of Rare Diseases”. • Internasjonalt initiativ, Cure4PMP-konsortiet: o Cure4PMP-møte med de engelske partnerne ved Hampshire Hospitals NHS Foundation Trust i Basingstoke, 13. mai 2015. o Cure4PMP-møte med de franske partnerne ved INSERM i Paris, 4. juni 2015. o Cure4PMP nettverket møttes for første gang med alle partnerne (fra Norge, England, Frankrike og Belgia) tilstede i Brüssel, 11. september 2015. • Andre internasjonale initiativer: o ESTRO-kongressen i Barcelona 24.-28. april 2015: Nettverk var representert blant annet med tanke på å finne aktuelle partnere for planlagt COST-søknad (EU nettverk). • ACREDIT seminarer/kurs/symposier: o 29. mai 2015 arrangerte ACREDIT en workshop innen immunologi hvor medlemmene kunne utveksle erfaringer og diskutere utfordringer og nye samarbeidsprosjekter. o 12. juni 2015 ble det avholdt et ACREDIT halvdagsmøte hvor medlemmene fikk oppdatering på de forskjellige studiene som inngår i nettverket. I tillegg ble søknadsmuligheter innen Horizon 2020 presentert og diskutert. o 25. november 2015 arrangerte ACREDIT et symposium med tittel Bioinformatics Applications in Colorectal Cancer Research. På programmet sto generell introduksjon av bioinformatikk og The Genomic Hyperbrowser. I tillegg var det presentasjoner av bruk av bioinformatikk innen pågående forskningsprosjekter i nettverket, samt en presentasjon fra Tjenester for Sensitive Data (TSD) ved Universitetet i Oslo. ACREDIT har som koordinator søkt følgende prosjekter i 2015: Project: Cure4PMP Specific Programme: "Cooperation" – Theme 1 "Health" Call identifier: H2020-PHC-14-2015-two-stage. New therapies for rare diseases Proposal No: 667890-1 Acronym: Cure4PMP Prosjekt: Cure4PMP Specific programme: NORD
2014
ACREDIT: Advanced ColoRectal Cancer – Individualization of Therapies With reference to the demography of colorectal cancer (CRC), owing to an aging population, this disease is common in both genders and among all adult age groups, but with a significant rise in incidence from the age of 60. In 2012, the CRC incidence rate in the Norwegian population of 5.0 million added up to more than 3,900 cases. Largely because of the demographic changes, there will be a steadily increasing call on clinical services, which also includes fiscal concerns. The management of the disease is multidisciplinary, involving precision diagnostics within radiology and pathology and highly specialized knowledge within oncology and surgery. Recognizing the high incidence rates and the therapeutic complexities, the impact of CRC on health services, nationally as well as globally, is significant. It will be crucial to develop sustainable approaches to tackle these challenges, including the bridging of rapidly emerging knowledge from basic biology into the optimum care of patients. Acknowledging failure of therapeutic control of CRC manifested by systemic disease dissemination, and further the scarcity of curative therapies in multi-organ metastatic disease, the principal aim of the research network is to exploit the functional information inherent in molecular and imaging biomarkers of advanced CRC to enable individualization of therapies based on actionable disease targets. The vision is to overcome a prevailing challenge – the lack of control of metastatic CRC. The strategy is to facilitate multidirectional flow of knowledge between clinical and basic research activities, with the overall objective to translate progress in cancer biology into clinical benefit. Individualization of CRC treatment appearing from contemporary molecular and imaging technologies requires an optimization of the traditional workflow in patient management. Important goals for the research network are therefore to strengthen the infrastructure and cross-disciplinary activities around patient management, and further to improve the network’s existing experience in clinical trial design and conduct of patient-adapted therapy, thereby creating the fundamental basis for the next-generation individualization of CRC treatment. A successful accomplishment of this program will be achieved by combining a wide range of experimental and clinical approaches that we have developed over the recent years within the research groups and together with international collaborators, with the opportunity of reaching a high international standard of the scientific activities on joining forces within a formalized research network. Our network research, which was established at a non-formalized level a decade ago, is currently organized through interdisciplinary activities involving medical specialists in oncology, gastroenterological surgery, and MR radiology, along with scientists (at the postdoctoral level or higher) qualified in biophysics, radiobiology, molecular and cell biology, and biotechnology. This structure, resulting from deliberate recruitment of network members, enables translational scientific exploitation of experimental models and unique clinical materials. The network activities address internationally emerging key issues within cancer care in general, which will continue to evolve from the management’s existing international collaborative activities. Also, the network holds a number of PhD student projects. Specifically, within the structure of ACREDIT, we anticipate to fulfill a number of ambitious achievements: 1. The preclinical search for actionable therapy targets and conduct of efficacy studies using our well-characterized in vitro (cell cultures) and in vivo (xenografts and orthotopic tumors) CRC models. 2. The conduct and accomplishment of a number of ongoing clinical CRC studies on identification of predictive biomarkers and evaluation of efficacy and toxicity of biologically targeted therapeutic intervention: i. Bone Marrow Micrometastases in Colorectal Cancer ii. LARC-RRP: Locally Advanced Rectal Cancer – Radiation Response Prediction (NCT00278694) iii. OxyTarget: Functional MRI of Hypoxia-mediated Rectal Cancer Aggressiveness (NCT01816607) iv. LARC-EX: Locally Advanced Rectal Cancer – Exfoliated Peritoneal Tumor Cells (NCT02113384) v. PRAVO: Pelvic Radiation and Vorinostat (NCT00455351) vi. Oslo-CoMet: Oslo Randomized Laparoscopic versus Open Liver Resection for Colorectal Metastases Study (NCT01516710) vii. ImmunoPeCa: Immunotoxin in Peritoneal Carcinomatosis (NCT02219893) viii. MetAction: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy (NCT02142036) 3. The strengthening of existing network activities, presently comprising regional and a limited number of international projects, in order to establish new international collaborative research projects to be conducted by the network. Specifically, the network will coordinate an application for the new EU framework program for research and innovation, Horizon 2020, to continue the scientific enterprise on personalized cancer medicine beyond the achievements from the METOXIA consortium (2009–2014), in which we have been partner [EU FP7 Grant 222741]. On invitations, we will also participate in projects coordinated from other European centers. The network will organize seminars and tutorial courses to disseminate research knowledge and advances in management of advanced CRC within the scientific and medical communities of the health region and nationally. To our ambition, at least one such symposium will be the starting point of an annual meeting series, with an international faculty, which in our opinion is absent from the national arena at present. Moreover, we will prioritize communication to the general public via establishment of an open website, as we believe the common interest in this topic is high, and further report new findings in national public media and by international news agencies. A digital platform for the daily communication within the network will also be established. Importantly, the network has shared projects, personnel, and infrastructure throughout its entire existence, and we envisage this to be further strengthened and exploited within a governing body that is formally endorsed at the level of Helse Sør-Øst. Since the ACREDIT initiative was funded, the following achievements have been reached: 1. A Project Coordinator, Siv Johnsen Soriano, PhD, was appointed from 1 May 2014. She will be responsible for organizing a number of activities; a few examples are to compile clinical study procedures, to assign and secure the required flow of information among participating departments and hospitals, to act as the study patients’ contact along treatment courses, to create and maintain network websites, and to plan and implement the network’s meeting calendar. 2. A kick-off meeting for all participants of the ACREDIT network was held on 8 October 2014. The intention was to bring together all members of the research groups within the network to be acquainted and to present the full project portfolio to everyone for comprehensive discussion among the participants. 3. The first meeting of the network Steering Group was held on 8 October 2014. The agenda comprised how to set a Scientific Advisory Board with international members, the possibility of taking the lead in a project within the context of a Cost Action call, and the feasibility of organizing a workshop or seminar among European groups involved in functional CRC imaging with the aim of initiating a COST Action initiative. 4. At the initiative of the network, a multidisciplinary meeting on the possibility of implementing a newly invented and patented functional MR imaging technology (Split Dynamic T1- and T2*-Weighted Contrast-Enhanced MR) within the Oslo-CoMet study was held at The Intervention Centre, Oslo University Hospital, on 28 November 2014. 5. The ACREDIT website has been launched: http://acredit.no/ 6. Three applications within Horizon 2020 calls have been submitted: i. As coordinator: ‘Cure4PMP’ within H2020-PHC-14-2015-two-stage/Health Programme; unfortunately not selected for a phase 2 application. ii. As participant: ‘SIST’ within H2020-PHC-11-2015-two-stage/Health Programme; unfortunately not selected for a phase 2 application. iii. As participant: ‘Cure4Cancer’ within H2020-PHC-13-2014-two-stage/Health Programme; approved for a phase 2 application but unfortunately not finally funded.
Vitenskapelige artikler
Hektoen HH, Ree AH, Redalen KR, Flatmark K

Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells.

J Enzyme Inhib Med Chem 2016 Oct;31(5):779-86. Epub 2015 aug 5

PMID: 26244271

Redalen KR, Sitter B, Bathen TF, Grøholt KK, Hole Kh, Dueland S, Flatmark K, Ree AH, Seierstad T

High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer.

Radiother Oncol 2016 Feb;118(2):393-8. Epub 2015 des 17

PMID: 26705680

Dueland S, Ree AH, Grøholt KK, Saelen MG, Folkvord S, Hole Kh, Seierstad T, Larsen SG, Giercksky KE, Wiig JN, Boye K, Flatmark K

Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome.

Clin Oncol (R Coll Radiol) 2016 Aug;28(8):532-9. Epub 2016 feb 14

PMID: 26888115

Flatmark K, Saelen MG, Hole Kh, Abrahamsen TW, Fleten KG, Hektoen HH, Redalen KR, Seierstad T, Dueland S, Ree AH

Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?

Radiother Oncol 2016 Jun;119(3):505-11. Epub 2016 mar 8

PMID: 26968754

Meltzer S, Kalanxhi E, Hektoen HH, Dueland S, Flatmark K, Redalen KR, Ree AH

Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer.

Oncotarget 2016 Jun 07;7(23):34907-17.

PMID: 27145458

Risberg K, Redalen KR, Sønstevold L, Bjørnetrø T, Sølvernes J, Ree AH

Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.

BMC Cancer 2016 Jul 26;16():531. Epub 2016 jul 26

PMID: 27461218

Kalanxhi E, Hektoen HH, Meltzer S, Dueland S, Flatmark K, Ree AH

Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening.

BMC Cancer 2016 Jul 26;16():536. Epub 2016 jul 26

PMID: 27461255

Kalanxhi E, Risberg K, Barua IS, Dueland S, Waagene S, Andersen SN, Pettersen SJ, Lindvall JM, Redalen KR, Flatmark K, Ree AH

Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy.

Cancer Res Treat 2017 Apr;49(2):374-386. Epub 2016 jul 28

PMID: 27488871

Ree AH

Immune-modulating cancer therapy - back to the future.

Tidsskr Nor Laegeforen 2016 Oct;136(19):1605. Epub 2016 okt 25

PMID: 27790877

Grøvik E, Redalen KR, Storås TH, Negård A, Holmedal SH, Ree AH, Meltzer S, Bjørnerud A, Gjesdal KI

Dynamic multi-echo DCE- and DSC-MRI in rectal cancer: Low primary tumor Ktrans and ΔR2* peak are significantly associated with lymph node metastasis.

J Magn Reson Imaging 2017 Jul;46(1):194-206. Epub 2016 des 21

PMID: 28001320

Frøysnes IS, Larsen SG, Spasojevic M, Dueland S, Flatmark K

Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort.

J Surg Oncol 2016 Aug;114(2):222-7. Epub 2016 mai 12

PMID: 27173150

Egeland EV, Flatmark K, Nesland JM, Flørenes VA, Mælandsmo GM, Boye K

Expression and clinical significance of Wee1 in colorectal cancer.

Tumour Biol 2016 Sep;37(9):12133-12140. Epub 2016 mai 24

PMID: 27220319

Boye K, Jacob H, Frikstad KA, Nesland JM, Maelandsmo GM, Dahl O, Nesbakken A, Flatmark K

Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy.

Cancer Med 2016 Aug;5(8):1840-9. Epub 2016 jun 8

PMID: 27273130

Barkhatov L, Fretland ÅA, Kazaryan AM, Røsok BI, Brudvik KW, Waage A, Bjørnbeth BA, Sahakyan MA, Edwin B

Validation of clinical risk scores for laparoscopic liver resections of colorectal liver metastases: A 10-year observed follow-up study.

J Surg Oncol 2016 Nov;114(6):757-763. Epub 2016 jul 29

PMID: 27471127

Flatmark K, Høye E, Fromm B

microRNAs as cancer biomarkers.

Scand J Clin Lab Invest Suppl 2016;245():S80-3. Epub 2016 aug 9

PMID: 27542003

Thorgersen EB, Goscinski MA, Spasojevic M, Solbakken AM, Mariathasan AB, Boye K, Larsen SG, Flatmark K

Deep Pelvic Surgical Site Infection After Radiotherapy and Surgery for Locally Advanced Rectal Cancer.

Ann Surg Oncol 2017 Mar;24(3):721-728. Epub 2016 okt 20

PMID: 27766561

Fleten KG, Bakke KM, Mælandsmo GM, Abildgaard A, Redalen KR, Flatmark K

Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases.

Clin Exp Metastasis 2017 01;34(1):51-62. Epub 2016 nov 3

PMID: 27812769

Ree AH, Flatmark K, Saelen MG, Folkvord S, Dueland S, Geisler J, Redalen KR

Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: opportunities for signaling-adapted therapies.

Crit Rev Oncol Hematol 2015 Jul;95(1):114-24. Epub 2015 jan 12

PMID: 25624177

Seierstad T, Hole Kh, Grøholt KK, Dueland S, Ree AH, Flatmark K, Redalen KR

MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer.

Br J Radiol 2015 Jul;88(1051):20150097. Epub 2015 apr 22

PMID: 25899892

Ree AH, Redalen KR

Personalized radiotherapy: concepts, biomarkers and trial design.

Br J Radiol 2015 Jul;88(1051):20150009. Epub 2015 mai 20

PMID: 25989697

Hektoen HH, Flatmark K, Andersson Y, Dueland S, Redalen KR, Ree AH

Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer.

BMC Cancer 2015;15():543. Epub 2015 jul 24

PMID: 26205955

Fromm B, Billipp T, Peck LE, Johansen M, Tarver JE, King BL, Newcomb JM, Sempere LF, Flatmark K, Hovig E, Peterson KJ

A Uniform System for the Annotation of Vertebrate microRNA Genes and the Evolution of the Human microRNAome.

Annu Rev Genet 2015 Nov 23;49():213-42. Epub 2015 okt 14

PMID: 26473382

Egeland EV, Boye K, Pettersen SJ, Haugen MH, Øyjord T, Malerød L, Flatmark K, Mælandsmo GM

Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes.

Clin Exp Metastasis 2015 Dec;32(8):755-67. Epub 2015 sep 9

PMID: 26349943

Fretland ÅA, Kazaryan AM, Bjørnbeth BA, Flatmark K, Andersen MH, Tønnessen TI, Bjørnelv GM, Fagerland MW, Kristiansen R, Øyri K, Edwin B

Open versus laparoscopic liver resection for colorectal liver metastases (the Oslo-CoMet Study): study protocol for a randomized controlled trial.

Trials 2015;16():73. Epub 2015 mar 4

PMID: 25872027

Haugen MH, Boye K, Nesland JM, Pettersen SJ, Egeland EV, Tamhane T, Brix K, Maelandsmo GM, Flatmark K

High expression of the cysteine proteinase legumain in colorectal cancer - implications for therapeutic targeting.

Eur J Cancer 2015 Jan;51(1):9-17. Epub 2014 nov 11

PMID: 25466510

Fretland AA, Sokolov A, Postriganova N, Kazaryan AM, Pischke SE, Nilsson PH, Rognes IN, Bjornbeth BA, Fagerland MW, Mollnes TE, Edwin B

Inflammatory Response After Laparoscopic Versus Open Resection of Colorectal Liver Metastases: Data From the Oslo-CoMet Trial.

Medicine (Baltimore) 2015 Oct;94(42):e1786.

PMID: 26496309

Nesgaard JM, Stimec BV, Bakka AO, Edwin B, Ignjatovic D,

Navigating the mesentery: a comparative pre- and per-operative visualization of the vascular anatomy.

Colorectal Dis 2015 Sep;17(9):810-8.

PMID: 25988347

Di Fabio F, Barkhatov L, Bonadio I, Dimovska E, Fretland ÅA, Pearce NW, Troisi RI, Edwin B, Abu Hilal M

The impact of laparoscopic versus open colorectal cancer surgery on subsequent laparoscopic resection of liver metastases: A multicenter study.

Surgery 2015 Jun;157(6):1046-54. Epub 2015 mar 31

PMID: 25835216

Wakabayashi G, Cherqui D, Geller DA, Buell JF, Kaneko H, Han HS, Asbun H, O'Rourke N, Tanabe M, Koffron AJ, Tsung A, Soubrane O, Machado MA, Gayet B, Troisi RI, Pessaux P, van Dam RM, Scatton O, Abu Hilal M, Belli G, Kwon CH, Edwin B, Choi GH, Aldrighetti LA, Cai X, Cleary S, Chen KH, Schön MR, Sugioka A, Tang CN, Herman P, Pekolj J, Chen XP, Dagher I, Jarnagin W, Yamamoto M, Strong R, Jagannath P, Lo CM, Clavien PA, Kokudo N, Barkun J, Strasberg SM

Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka.

Ann Surg 2015 Apr;261(4):619-29.

PMID: 25742461

Andersson Y, Engebraaten O, Juell S, Aamdal S, Brunsvig P, Fodstad Ø, Dueland S

Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin.

Br J Cancer 2015 Dec 1;113(11):1548-55. Epub 2015 nov 10

PMID: 26554649

Venugopal B, Awada A, Evans TR, Dueland S, Hendlisz A, Rasch W, Hernes K, Hagen S, Aamdal S

A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours.

Cancer Chemother Pharmacol 2015 Oct;76(4):785-92. Epub 2015 aug 20

PMID: 26289594

Line PD, Hagness M, Berstad AE, Foss A, Dueland S

A Novel Concept for Partial Liver Transplantation in Nonresectable Colorectal Liver Metastases: The RAPID Concept.

Ann Surg 2015 Jul;262(1):e5-9.

PMID: 25692361

Dueland S, Hagness M, Line PD, Guren TK, Tveit KM, Foss A

Is Liver Transplantation an Option in Colorectal Cancer Patients with Nonresectable Liver Metastases and Progression on All Lines of Standard Chemotherapy?

Ann Surg Oncol 2015 Jul;22(7):2195-200. Epub 2014 okt 9

PMID: 25297902

Dueland S, Guren TK, Hagness M, Glimelius B, Line PD, Pfeiffer P, Foss A, Tveit KM

Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer?

Ann Surg 2015 May;261(5):956-60.

PMID: 24950280

Ree Anne Hansen, Saelen Marie Grøn, Kalanxhi Erta, Østensen Ingrid H G, Schee Kristina, Røe Kathrine, Abrahamsen Torveig Weum, Dueland Svein, Flatmark Kjersti

Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy.

PLoS One 2014;9(2):e89750. Epub 2014 feb 25

PMID: 24587009

Pettersen Erik O, Ebbesen Peter, Gieling Roben G, Williams Kaye J, Dubois Ludwig, Lambin Philippe, Ward Carol, Meehan James, Kunkler Ian H, Langdon Simon P, Ree Anne H, Flatmark Kjersti, Lyng Heidi, Calzada Maria J, Peso Luis Del, Landazuri Manuel O, Görlach Agnes, Flamm Hubert, Kieninger Jochen, Urban Gerald, Weltin Andreas, Singleton Dean C, Haider Syed, Buffa Francesca M, Harris Adrian L, Scozzafava Andrea, Supuran Claudiu T, Moser Isabella, Jobst Gerhard, Busk Morten, Toustrup Kasper, Overgaard Jens, Alsner Jan, Pouyssegur Jacques, Chiche Johanna, Mazure Nathalie, Marchiq Ibtissam, Parks Scott, Ahmed Afshan, Ashcroft Margaret, Pastorekova Silvia, Cao Yihai, Rouschop Kasper M, Wouters Brad G, Koritzinsky Marianne, Mujcic Hilda, Cojocari Dan

Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium.

J Enzyme Inhib Med Chem 2014 Oct 27. Epub 2014 okt 27

PMID: 25347767

Ree Anne Hansen, Meltzer Sebastian, Flatmark Kjersti, Dueland Svein, Kalanxhi Erta

Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks.

Int J Mol Sci 2014;15(12):22835-56. Epub 2014 des 9

PMID: 25501337

Sørensen Olaf, Andersen Anders Mikal, Kristian Alexandr, Giercksky Karl-Erik, Flatmark Kjersti

Impact of hyperthermia on pharmacokinetics of intraperitoneal mitomycin C in rats investigated by microdialysis.

J Surg Oncol 2014 May;109(6):521-6. Epub 2013 des 17

PMID: 24347444

Ingebrigtsen Vibeke A, Boye Kjetil, Nesland Jahn M, Nesbakken Arild, Flatmark Kjersti, Fodstad Øystein

B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome.

BMC Cancer 2014;14():602. Epub 2014 aug 20

PMID: 25139714

Hagness Morten, Foss Aksel, Egge Tor Skatvedt, Dueland Svein

Patterns of recurrence after liver transplantation for nonresectable liver metastases from colorectal cancer.

Ann Surg Oncol 2014 Apr;21(4):1323-9. Epub 2013 des 27

PMID: 24370906

Raabe Nils Kristian, Sundfør Kolbein, Hole Knut Håkon, Djupvik Linda Holth, Larsen Stein Gunnar, Dueland Svein

[High-dose-rate brachytherapy in recurrent rectal cancer after conventional recurrence treatment].

Tidsskr Nor Laegeforen 2014 Oct 28;134(20):1929-30. Epub 2014 okt 28

PMID: 25350435

Guren Marianne Grønlie, Undseth Christine, Rekstad Bernt Louni, Brændengen Morten, Dueland Svein, Spindler Karen-Lise Garm, Glynne-Jones Rob, Tveit Kjell Magne

Reirradiation of locally recurrent rectal cancer: a systematic review.

Radiother Oncol 2014 Nov;113(2):151-7. Epub 2014 nov 26

PMID: 25613395

Postriganova Nadya, Kazaryan Airazat M, Røsok Bård I, Fretland Åsmund A, Barkhatov Leonid, Edwin Bjørn

Margin status after laparoscopic resection of colorectal liver metastases: does a narrow resection margin have an influence on survival and local recurrence?

HPB (Oxford) 2014 Sep;16(9):822-9. Epub 2013 des 6

PMID: 24308605

Courivaud Frédéric, Kazaryan Airazat M, Lund Alice, Orszagh Vivian C, Svindland Aud, Marangos Irina Pavlik, Halvorsen Per Steinar, Jebsen Peter, Fosse Erik, Hol Per Kristian, Edwin Bjørn

Thermal fixation of swine liver tissue after magnetic resonance-guided high-intensity focused ultrasound ablation.

Ultrasound Med Biol 2014 Jul;40(7):1564-77. Epub 2014 apr 24

PMID: 24768489

Doktorgrader
Helga Helseth Hektoen

Translational studies of microenvironmental factors in rectal cancer with emphasis on tumor hypoxia

Disputert:
oktober 2015
Hovedveileder:
Anne Hansen Ree
Marie Grøn Sælen

Rectal cancer – Functional Molecular Profiling and Targeting of Tumor Hypoxia in Radiation Response and Metastasis

Disputert:
juni 2014
Hovedveileder:
Anne Hansen Ree
Deltagere
  • Siv Johnsen Soriano Prosjektdeltaker
  • Bjørn Edwin Forskningsgruppeleder
  • Svein Dueland Forskningsgruppeleder
  • Arne Sigmund Borthne Forskningsgruppeleder
  • Kathrine Røe Redalen Forsker (annen finansiering)
  • Kjersti Flatmark Forskningsgruppeleder
  • Anne Hansen Ree Prosjektleder

eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT

Alle henvendelser rettes til eRapport

Personvern  -  Informasjonskapsler